NCT02905903View on ClinicalTrials.gov

An In Vivo Model for Postinflammatory Hyperpigmentation

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 14, 2016

Primary Completion Date

May 16, 2018

Study Completion Date

June 21, 2019

Conditions
Post-inflammatory Hyperpigmentation
Interventions
DRUG

Tricholoacetic Acid (TCA)

We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.

Trial Locations (1)

48202

Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard,, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER

NCT02905903 - An In Vivo Model for Postinflammatory Hyperpigmentation | Biotech Hunter | Biotech Hunter